Augustine Bourne

Augustine Bourne currently serves as Vice President of Business Development at Sapience Therapeutics, Inc., a position held since December 2024. Prior to this role, Augustine was instrumental in business development and corporate strategy at Mirati Therapeutics from January 2021 until December 2024, where efforts contributed to significant partnership activities during the company's acquisition by BMS for up to $5.8 billion in January 2024. Augustine held the position of Director of Business Development at Regeneron from January 2016 to December 2021, focusing on hematology and antibody platform technologies. Earlier experience includes an MBA Associate role in oncology marketing at Gilead Sciences and serving as a Corporate Attorney at Weil, Gotshal & Manges LLP from January 2007 to December 2014. Educational qualifications include a Master's in Business Administration from Columbia Business School and a Master's in Molecular and Cellular Biochemistry from the University of Oxford.